Russo Roberta, Marra Roberta, Rosato Barbara Eleni, Iolascon Achille, Andolfo Immacolata
Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Naples, Italy.
CEINGE Biotecnologie Avanzate, Naples, Italy.
Front Physiol. 2020 Dec 22;11:613559. doi: 10.3389/fphys.2020.613559. eCollection 2020.
The hereditary anemias are a relatively heterogeneous set of disorders that can show wide clinical and genetic heterogeneity, which often hampers correct clinical diagnosis. The classical diagnostic workflow for these conditions generally used to start with analysis of the family and personal histories, followed by biochemical and morphological evaluations, and ending with genetic testing. However, the diagnostic framework has changed more recently, and genetic testing is now a suitable approach for differential diagnosis of these patients. There are several approaches to this genetic testing, the choice of which depends on phenotyping, genetic heterogeneity, and gene size. For patients who show complete phenotyping, single-gene testing remains recommended. However, genetic analysis now includes next-generation sequencing, which is generally based on custom-designed targeting panels and whole-exome sequencing. The use of next-generation sequencing also allows the identification of new causative genes, and of polygenic conditions and genetic factors that modify disease severity of hereditary anemias. In the research field, whole-genome sequencing is useful for the identification of non-coding causative mutations, which might account for the disruption of transcriptional factor occupancy sites and regulatory elements. Moreover, advances in high-throughput sequencing techniques have now resulted in the identification of genome-wide profiling of the chromatin structures known as the topologically associating domains. These represent a recurrent disease mechanism that exposes genes to inappropriate regulatory elements, causing errors in gene expression. This review focuses on the challenges of diagnosis and research into hereditary anemias, with indications of both the advantages and disadvantages. Finally, we consider the future perspectives for the use of next-generation sequencing technologies in this era of precision medicine.
遗传性贫血是一组相对异质性的疾病,可表现出广泛的临床和遗传异质性,这常常妨碍正确的临床诊断。这些疾病的经典诊断流程通常从分析家族史和个人史开始,接着进行生化和形态学评估,最后进行基因检测。然而,最近诊断框架发生了变化,基因检测现在是这些患者鉴别诊断的合适方法。基因检测有几种方法,其选择取决于表型分析、遗传异质性和基因大小。对于表现出完整表型的患者,仍推荐单基因检测。然而,基因分析现在包括新一代测序,其通常基于定制设计的靶向panel和全外显子组测序。新一代测序的应用还能够识别新的致病基因,以及多基因疾病和影响遗传性贫血疾病严重程度的遗传因素。在研究领域,全基因组测序有助于识别非编码致病突变,这些突变可能导致转录因子占据位点和调控元件的破坏。此外,高通量测序技术的进展现已导致识别出称为拓扑相关结构域的全基因组染色质结构图谱。这些代表了一种反复出现的疾病机制,使基因暴露于不适当的调控元件,导致基因表达错误。本综述重点关注遗传性贫血的诊断和研究挑战,并指出其优缺点。最后,我们考虑了在这个精准医学时代使用新一代测序技术的未来前景。